Idarucizumab

Category: Blood Clotting (Hemostasis)



Idarucizumab Overview

Idarucizumab (BI 655075), sold under the brand name Praxbind, is a monoclonal antibody designed for the reversal of anticoagulant effects of dabigatran.[1][2] This drug was developed by Boehringer Ingelheim Pharmaceuticals. A large study sponsored by the manufacturer found that idarucizumab effectively reversed anticoagulation by dabigatran within minutes.[3] It was FDA approved in October 2015.[4] In the United States the wholes...

Read more Idarucizumab Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Idarucizumab

Recent Idarucizumab Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Idarucizumab
  • Injection: 2.5g/50ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Idarucizumab or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 21 January 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA